2. Signaling Pathways
  3. Immunology/Inflammation
  4. VISTA

VISTA

V-domain Ig suppressor of T cell activation (VISTA)

V-domain immunoglobulin suppressor of T cell activation (VISTA) is a novel inhibitory immune checkpoints (ICs) that is expressed on myeloid cells, lymphoid cells, and tumoral cells; therefore, VISTA can substantially regulate innate and

adaptive anti-tumoral immune responses. VISTA is a transmembrane protein that plays a crucial role in the regulation of antitumor immunity. Therapeutic intervention that inhibits the VISTA pathway constitutes a new approach in the treatment of cancer.

VISTA Related Products (13):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P99040
    Onvatilimab
    		Inhibitor 98.00%
    Onvatilimab (JNJ-61610588) is a human IgG1κ anti-VISTA (V-domain Ig Suppressor of T-cell Activation) monoclonal antibody. Onvatilimab can be used in colorectal cancer research.
    Onvatilimab
  • HY-P990145
    Anti-Mouse VISTA Antibody (13F3)
    		Inhibitor
    Anti-Mouse VISTA Antibody (13F3) is an anti-mouse VISTA IgG monoclonal antibody. Anti-Mouse VISTA Antibody (13F3) can reverse the immunosuppressive effect of VISTA by blocking its binding to ligands such as VSIG3. Anti-Mouse VISTA Antibody (13F3) exacerbates pulmonary fibrosis (PF) by promoting Th17 cell differentiation. Anti-Mouse VISTA Antibody (13F3) can be used for research on cancer such as breast cancer and PF.
    Anti-Mouse VISTA Antibody (13F3)
  • HY-169853
    M351-0056
    		Agonist 99.48%
    M351-0056 is the agonist for the immune checkpoint protein VISTA, that reduces the secretion of VISTA-induced cytokines, promotes the T-cell proliferation induced by VISTA, and exhibits immunomodulatory activity. M351-0056 ameliorates Imiquimod (HY-B0180)-induced psoriatic dermatitis in mouse models.
    M351-0056
  • HY-179630
    MS102
    		Inhibitor
    MS102 is an orally active ubiquitin specific peptidase 2 (USP2) inhibitor with an IC50 of 5.46 μM. MS102 has viable antiviral activity against ACE2-dependent coronaviruses. MS102 significantly reduces V-domain Ig suppressor of T cell activation (VISTA) protein abundance in vitro and in vivo. MS102 can be used for the study of SARS-CoV-2. MS102 can be used in combination with anti-PD-1 immunotherapy to enhance the anti-tumor immune response.
    MS102
  • HY-P991776
    Anti-Mouse VISTA Antibody (8G8)
    		Inhibitor 98.26%
    Anti-Mouse VISTA Antibody (8G8) reacts with mouse VISTA. Anti-Mouse VISTA Antibody (8G8) is an agonistic antibody with immunosuppressive properties. Recommend Isotype Controls: Polyclonal Armenian hamster IgG, Isotype Control (HY-P990305).
    Anti-Mouse VISTA Antibody (8G8)
  • HY-P991765
    Anti-VISTA Antibody (GG8)
    		Inhibitor
    Anti-VISTA Antibody (GG8) reacts with human VISTA. Endogenous VISTA has inhibitory effects both as a ligand on APCs and as a receptor on T cells. Recommend Isotype Controls: Mouse IgG1 kappa, Isotype Control (HY-P99977).
    Anti-VISTA Antibody (GG8)
  • HY-Q25865
    MG-V-53
    		Inhibitor
    MG-V-53 is a potent small molecule V domain T-cell activating immunoglobulin suppressor (VISTA) inhibitor with IC50 value of 121 nM. MG-V-53 has antitumor activity.
    MG-V-53
  • HY-P991447
    Anti-VSIR/VISTA Antibody (SG7)
    		Inhibitor
    Anti-VSIR/VISTA Antibody (SG7) is a human monoclonal antibody (mAb) targeting VISTA/B7-H5. Anti-VSIR/VISTA Antibody (SG7) inhibits VISTA function and prevents PSGL-1 and VSIG3 from binding to VISTA. Anti-VSIR/VISTA Antibody (SG7) has anti-tumor activity in the mouse B16F10 melanoma model. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-VSIR/VISTA Antibody (SG7)
  • HY-172396
    PD-L1/VISTA-IN-2
    		Inhibitor
    PD-L1/VISTA-IN-2 (Compound S8) is an orally active bifunctional PD-L1/VISTA inhibitor with an IC50 of 1.4 μM for PD-L1 and a KD of 2.1 μM for VISTA. PD-L1/VISTA-IN-2 can activate the tumor immune microenvironment and exert anti-cancer effects.
    PD-L1/VISTA-IN-2
  • HY-P11253
    DOTA-Bn-CA-170
    DOTA-Bn-CA-170 is a molecular probe targeting the VISTA protein, with a Kd value of 0.124 nM. DOTA-Bn-CA-170 is formed by covalently linking the p-SCN-Bn-DOTA ligand with CA-170 (HY-101093). DOTA-Bn-CA-170 labeled with [68Ga]Ga successfully achieves specific and high-contrast PET imaging of VISTA expression in various tumor-bearing mouse models. DOTA-Bn-CA-170 can be used for the study of VISTA-targeted immunotherapy.
    DOTA-Bn-CA-170
  • HY-170793
    PD-L1/VISTA-IN-1
    		Inhibitor
    PD-L1/VISTA-IN-1 (Compound P17) is an orally active dual-target inhibitor of PD-L1 and VISTA. PD-L1/VISTA-IN-1 can block the PD-1/PD-L1 interaction (IC50: 0.1492 μM) and the VISTA pathway (KD: 0.2723 μM), thereby reactivating T cells. PD-L1/VISTA-IN-1 has anti-tumor activity.
    PD-L1/VISTA-IN-1
  • HY-P11252
    DOTA-CA-170
    		Ligand
    DOTA-CA-170 is a DOTA-modified VISTA targeting agent CA-170. DOTA-CA-170 can be radiolabeled. DOTA-CA-170 can be used in the research of visualizing and distinguishing VISTA expression.
    DOTA-CA-170
  • HY-P991421
    W0180
    		Inhibitor
    W0180 is a human IgG1 monoclonal antibody (mAb) targeting VISTA/B7-H5. W0180 has the potential to activate T cells. W0180 can be used in solid tumors research.
    W0180